For developers working to bring gene therapies to market, this is no small challenge. Manufacturing scale affects not only supply, but also cost per dose, process robustness, product quality, and regulatory readiness. In this interview, Samuel Hernandez, PhD, SVP Site Head at FUJIFILM Biotechnologies’ Texas facility, discusses how scaling AAV production to 2,000 L single-use bioreactors can help address those barriers and support a more commercially viable path for gene therapy innovators.